{"prompt": "['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', '14.', 'DIRECT ACCESS TO SOURCE DATA/DOCUMENTS', '14.1.', 'Study Monitoring', 'Before an investigational site can enter a subject into the study, a representative of the Sponsor', '(or designee; as applicable) may visit the investigational study site to:', 'Determine the adequacy of the facilities', 'Discuss with the Investigator and other personnel their responsibilities with regard to', 'protocol adherence, and the responsibilities of the Sponsor or its representatives. This', 'will be documented in a Clinical Study Agreement between the Sponsor and the', 'Investigator.', 'During the study, a monitor from the Sponsor (or designee) or representative will have regular', 'contacts with the investigational site, for the following:', 'Provide information and support to the Investigator', 'Confirm that facilities remain acceptable', 'Confirm that the investigational team is adhering to the protocol, that data are being', 'accurately recorded in the CRF/eCRF, and that IP accountability checks are being', 'performed', 'Perform source data verification. This includes a comparison of the data in the', \"CRFs/eCRFs with the subject's medical records at the hospital or practice, and other\", 'records relevant to the study. This will require direct access to all original records for', 'each subject (eg, clinic charts).', 'Record and report any protocol deviations not previously sent to the Sponsor.', 'Confirm AEs and SAEs have been properly documented on CRFs/eCRFs and', 'confirm any SAEs have been forwarded to the Sponsor and those SAEs that met', 'criteria for reporting have been forwarded to the IRB.', 'Any other monitoring tasks, as appropriate', 'The monitor will be available between visits if the Investigator or other staff needs', 'information or advice.', '14.2.', 'Audits and Inspections', 'Authorized representatives of the Sponsor (or designee), a regulatory authority, an IEC or an IRB', 'may visit the site to perform audits or inspections, including source data verification. The', 'Investigator should contact the Sponsor (or designee) immediately if contacted by a regulatory', 'agency about an inspection.', '14.2.1.', 'Inspection', 'An inspection is defined as the act of a regulatory authority of conducting an official review of', 'documents, facilities, records and any other resources that are deemed by the authorities to be', \"related to the clinical study and that may be located at the site of the study, or at the Sponsor's\", 'Glenmark', 'CONFIDENTIAL', 'Page 66 of 90']['Study Number: GSP 301-305', 'Version 3.0', 'Date 18-Jul-2018', 'and/or CRO facilities or any other establishments deemed appropriate by the regulatory', 'authorities.', '14.2.2.', 'Audit', 'An audit is a systematic and independent review of study-related activities and documents to', 'determine whether study-related activities were conducted and the data were accurately recorded', 'and analyzed according to the protocol, standard operating procedures, GCP, and the appropriate', 'requirements.', 'In conducting this study the Investigator accepts that the Sponsor, IRB/IEC or regulatory body', 'may, at any time by appointment, conduct an audit of the study site.', '14.3.', 'Institutional Review Board/Independent Ethics Committee', 'The Investigator must obtain IRB/IEC approval for the clinical study. Initial IRB/IEC approval,', 'and all materials approved by the IRB/IEC for this study including the subject consent form and', 'recruitment materials must be maintained by the Investigator and made available for inspection.', '15.', 'QUALITY CONTROL AND QUALITY ASSURANCE', 'To ensure compliance with Good Clinical Practices and all applicable regulatory requirements,', 'The Sponsor may conduct a quality assurance audit. Please see Section 14.2 for more details', 'regarding the audit process.', '16.', 'ETHICS', '16.1.', 'Ethics Review', 'The final study protocol, including the final version of the ICF, must be approved or given a', 'favorable opinion in writing by an IRB or IEC as appropriate. The Investigator must submit', 'written approval to the Sponsor (or designee) before he or she can enroll any subject into the', 'study.', 'The Investigator is responsible for informing the IRB or IEC of any amendment to the protocol', 'in accordance with local requirements. In addition, the IRB or IEC must approve all advertising', 'material used to recruit subjects for the study, as well as any materials (eg subject diaries, subject', 'questionnaires) to be given to subjects. The protocol must be re-approved by the IRB or IEC', 'upon receipt of amendments and annually, as local regulations require.', 'The Investigator is also responsible for providing the IRB or IEC with reports of any reportable', 'serious adverse drug reactions from any other study conducted with the IP. The Sponsor (or', 'designee) will provide this information to the Investigator.', 'Progress reports and notifications of serious adverse drug reactions will be provided to the IRB', 'or IEC according to local regulations and guidelines.', 'In the case of early termination/temporary halt of the study, the Investigator or Sponsor should', 'notify the IRB/IEC and Regulatory Authority in accordance with applicable regulatory', 'Glenmark', 'CONFIDENTIAL', 'Page 67 of 90']\n\n###\n\n", "completion": "END"}